3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Terminated
1
Sponsor Class
NIH
3
OTHER
2
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Lymphoid
7
Other hematologic neoplasm
5
Thoracic
3
Sarcoma
3
Gynecologic
3
Genitourinary
3
Plasma cell
2
Other solid neoplasm
2
Head & Neck
2
Gastrointestinal
2
Breast
2
Tumor-Agnostic
1
Dermatologic
1
Conditions
Lymphoma, T-Cell, Peripheral
1
Lymphoma, T-Cell, Cutaneous
1
Lymphoma, Non-Hodgkin
1
Lymphoma
1
Interventions
pembrolizumab
181
Nivolumab
117
Ipilimumab
97
Dacarbazine
48
trametinib
37
dabrafenib
35
3-ingenyl angelate
35
Vemurafenib
33
cemiplimab
27
atezolizumab
24
Temozolomide
24
binimetinib
23
Paclitaxel
22
Imiquimod
22
encorafenib
17
avelumab
17
Carboplatin
17
Aminolevulinic Acid
17
spartalizumab
16
cobimetinib
16
Cyclophosphamide
15
Cisplatin
15
Fluorouracil
14
talimogene laherparepvec
13
HhAntag691
11
Gels
11
Drug Therapy
11
Bevacizumab
11
lenvatinib
10
durvalumab
10
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
INDUSTRY
×
belinostat
×
Dermatologic
×
Clear all
NCT00274651
2015-07-28
PXD101-CLN-6
Valerio Therapeutics
Phase 2
Terminated
53 enrolled
12 charts